One year immunotherapy with high doses of interleukin-2 after autologous bone marrow transplantation in neuroblastoma stage IV childhood patients. I. Monitoring the parameters of toxicity and clinical response

N. Pardo Garcia, F. Marti Aliu, G. Fraga Rodriguez, J. Illa Sala, M. Peiro Moya, E. Bertran Rodriguez, B. Amill Camps, J. Garcia Lopez, F. Rueda Palacio, J. Cubells Riero

Research output: Contribution to journalArticleResearchpeer-review

Abstract

The aim of this study was to maintain the levels of Natural Killer (NK) activity higher than control values for one year, by the systemic administration of interleukin-2 (IL2), in patients with stage IV neuroblastoma after autologous bone marrow transplantation. We administered IL2 treatment at a dose of 18 x 10 6 UI/m 2 /day given by continuous infusion over a five day period. The toxicity and clinical response to 17 cycles of treatment was analyzed in 3 patients. At the start of each new cycle, the periodicity of IL2 administration was adapted according to the levels of NK. All cycles were followed by fever, asthenia, skin lesions and liver enlargement. Anaemia, thrombopenia, leucocytosis with an excess of eosinophils were the major hematological modifications. All types of toxicity were transient and no life-threatening complications were observed under intensive care conditions. We conclude that IL2 can be administered safely and could be a way to eliminate the minimal residual tumoral disease in these patients.
Original languageEnglish
Pages (from-to)23-29
JournalAnales Espanoles de Pediatria
Volume43
Issue number1
Publication statusPublished - 24 Aug 1995

Keywords

  • autologous bone marrow transplantation
  • immunotherapy
  • interleukin-2
  • Natural Killer
  • neuroblastoma

Fingerprint Dive into the research topics of 'One year immunotherapy with high doses of interleukin-2 after autologous bone marrow transplantation in neuroblastoma stage IV childhood patients. I. Monitoring the parameters of toxicity and clinical response'. Together they form a unique fingerprint.

  • Cite this

    Pardo Garcia, N., Marti Aliu, F., Fraga Rodriguez, G., Illa Sala, J., Peiro Moya, M., Bertran Rodriguez, E., Amill Camps, B., Garcia Lopez, J., Rueda Palacio, F., & Cubells Riero, J. (1995). One year immunotherapy with high doses of interleukin-2 after autologous bone marrow transplantation in neuroblastoma stage IV childhood patients. I. Monitoring the parameters of toxicity and clinical response. Anales Espanoles de Pediatria, 43(1), 23-29.